Log In
Print
BCIQ
Print
Print this Print this
 

Immuno-PDT, verteporfin (Visudyne) (BPD-MA)

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionLight-activated benzoporphyrin derivative used in photodynamic therapy (PDT)
Molecular Target Not available
Mechanism of ActionPhotodynamic therapy
Therapeutic ModalityMedical Devices: Photodynamic therapy
Latest Stage of DevelopmentMarketed
Standard IndicationChoroidal neovascularization (CNV)
Indication DetailsTreat choroidal neovascularization (CNV); Treat chronic or recurrent central serous chorioretinopathy (CSC); Treat occult choroidal neovascularization (CNV) due to age-related macular degeneration (AMD); Treat occult subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD); Treat patients with evidence of recent or ongoing progression in occult subfoveal choridal neovascularization (CNV); Treat polypoidal choroidal vasculopathy (PCV); Treat predominantly classic subfoveal chorodial neovascularization (CNV); Treat subfoveal choroidal neovascularization (CNV) secondary to wet age-related macular degeneration (AMD)
Regulatory Designation U.S. - Orphan Drug (Treat chronic or recurrent central serous chorioretinopathy (CSC))
Partner Novartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$112.5M

$20.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today